HIN SANG GROUP (INTERNATIONAL) HOLDING CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.32 HKD | 0.00% |
|
-3.03% | -4.48% |
| Feb. 19 | Hin Sang Group (International) Holding Co. Ltd. Announces Change of Company Secretary, Effective 19 February 2024 | CI |
| 2023 | Hin Sang Group Narrows Fiscal H1 Loss | MT |
| Sales 2022 | 121M 15.39M | Sales 2023 | 81.46M 10.4M | Capitalization | 426M 54.37M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -1.4M | Net income 2023 | -49M -6.26M | EV / Sales 2022 | 5.14 x |
| Net Debt 2022 | 303M 38.67M | Net Debt 2023 | 305M 39.01M | EV / Sales 2023 | 8.98 x |
| P/E ratio 2022 |
-26.6
x | P/E ratio 2023 |
-8.6
x | Employees | 265 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 25.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.03% | ||
| 3 months | +16.36% | ||
| 6 months | -15.79% | ||
| Current year | -4.48% |
1 week
0.28
0.33
1 month
0.280.33
Current year
0.240.36
1 year
0.240.46
3 years
0.240.75
5 years
0.241.00
10 years
0.243.03
| Managers | Title | Age | Since |
|---|---|---|---|
Siu Hin Pang
CEO | Chief Executive Officer | 59 | 10-09-30 |
Wing Keung Mak
CTO | Chief Tech/Sci/R&D Officer | 57 | 04-04-30 |
Lai Man Kwan
BRD | Director/Board Member | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Luk Shiu Lee
BRD | Director/Board Member | 66 | 14-09-24 |
Chi Kit Lau
BRD | Director/Board Member | 79 | 17-10-15 |
Wai Ling Wong
BRD | Director/Board Member | 63 | 10-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.32 | 0.00% | 2 000 |
| 24-04-17 | 0.32 | -3.03% | 6,000 |
| 24-04-16 | 0.33 | 0.00% | 0 |
| 24-04-15 | 0.33 | 0.00% | 0 |
| 24-04-12 | 0.33 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 18, 2024 at 04:08 am EDT
More quotes
Hin Sang Group (International) Holding Co. Ltd. is an investment holding company principally engaged in development, marketing and sales of care products, healthcare products and household products under various brands. The Company operates its business through three segments. The Product Development segment is engaged in the sales of products developed by the Company under own brands. The Brand Development and Management segment is engaged in the sales and distribution of products with exclusive distribution rights. The Trading of Goods segment is engaged in the sales and distribution of products purchased from authorized dealers, independent traders, manufacturers and parallel importers.
Sector
Pharmaceuticals
Calendar
2024-06-24
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.48% | 44.61M | |
| +28.79% | 676B | |
| +24.15% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +3.13% | 210B | |
| -0.28% | 204B | |
| -9.57% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- 6893 Stock
